Drugs / CD19-CAR-T2 Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02822326 | Jan 2016 → Sep 2019 | acute leukemia | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04605666 | May 2020 → Jun 2023 | B-cell acute lymphoblastic leukemia | Nanfang Hospital, Southern Medical University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR-T2 Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02822326 ↗ |
| Action | Deplete | “The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells).” NCT02822326 ↗ |
| Modality | Cell therapy | “1928zT2 T cells were generated by 19-28z-TLR2 lentiviral vector transfection into primary human T lymphocytes.” PMID 29458388 ↗ Feb 2018 |
| Target | CD19 | “to generate 1928zT2 T cells targeting CD19” PMID 29458388 ↗ Feb 2018 |